Ключевые слова:
ХОБЛ; обострения; C-реактивный белок; CRP; CLR; LCR; нейтрофильно-лимфоцитарное соотношение; NLR; CAT; mMRC; системное воспаление.Библиографические ссылки
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD: 2025 Report.
Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2010.
Hurst JR. Susceptibility to exacerbation in COPD. Lancet Respir Med. 2017.
Leuzzi G, Galeone C, Taverna F, et al. C-reactive protein level predicts mortality in COPD. Eur Respir Rev. 2017.
Dahl M, Tybjærg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. C-reactive protein as a predictor of prognosis in COPD. Am J Respir Crit Care Med. 2007.
Silva DR, Gazzana MB, Knorst MM. C-reactive protein levels in stable COPD patients. (обзор/ исследование).
Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable COPD. 2008.
Kon SSC, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test (CAT). 2014.
CAT Governance Board. CAT Healthcare Professional User Guide.
(Источник по валидности/применению mMRC в ХОБЛ).
Zinellu A, Mangoni AA. Systematic review/meta-analysis: NLR and adverse outcomes in COPD. 2022.
Pascual-González Y, et al. Systematic review: role of NLR in COPD. 2018.
Paliogiannis P, et al. Meta-analysis: NLR in stable COPD vs controls. 2018.
ERS/ATS. Guidelines for the management of COPD exacerbations. 2017.
Evensen A. Management of COPD Exacerbations. Am Fam Physician. 2010.
(Источник по CRP при AECOPD/инфекционном компоненте).
Ao T, et al. Association between CRP-to-lymphocyte ratio (CLR) and COPD. 2025.
Ullah W, et al. Lymphocyte-to-CRP ratio (LCR) as inflammation marker (clinical outcomes context). 2020.
(Источник по внутрииндивидуальной вариабельности CRP).
McGarvey L, et al. Characterisation of the frequent exacerbator phenotype in COPD. 2015.